Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ raptor resources limited

RAP - The Main Game, page-515

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 515 Last

Share
Profile

Follow
Tech goose

2,710 Posts.

506

06/02/17

18:50

Post #: 22407863
Share

Originally posted by DueDili ↑

Hello All

Junior Doc here. Been reading through the last few pages and all the speculation on what us Drs will do with this app has given me a bit of a chuckle.

To start off, I think this is a very exciting app and technology, and has the potential to be a leader in the tele-health revolution.

However, I don't believe this technology will change clinical medicine a whole lot, and certainly not in the short term.

It is important to understand that when we see a patient face to face, yes we listen with our stethoscopes. But that is only to get a general idea as to what is going on. I personally, and most if not all Drs would not base any diagnosis or start treatment based only off what we hear with stethoscopes. Our diagnosis is supplemented with further Ix such as Chest Xrays or CT scans. It is important to understand that our stethoscopes are such TOOLS, the same as Imaging, the same as ResAPP. They are all diagnosis TOOLS. We collect the data from all our tools to come up with the diagnosis.

So if you're thinking clinical Drs will suddenly be whipping out our smart phones and using ResAPP or any other tool to singularly diagnose any medical condition, you have misunderstood how Drs operate. I don't think we will be saying "Have you gotten the ResAPP ©® diagnosis" for at least 5-10 years.

As with any new technology, they are initially expensive to license to use. I expect the same with ResAPP. There is simply no incentive, especially for public hospitals here in Australia which all have their budgets at redline, to use ResAPP whilst it is such a new technology. We simply have an abundance of cheaper tools available to us that will be able to lead to the same Dx, i.e. cheap Xrays + clinical presentation.

Similarly for the local GP clinics, or even superclinics, there is no incentive to use this tool. When in doubt, the GP will simply prescribe antibiotics. Now if GPs were getting sued left right and centre for misdiagnosis of pneumonia (serious lung infection), sure, there might be a financial and security incentive to use ResAPP, but they aren't getting sued. The GP will also sent the pt off for cheap Xrays, and in the mean time simply cover the possibility to a lung infection with antibiotics.

All in all, yes, this is a very exciting app. BUT I believe the most excitement will still be in the tele-health world were doing things like listening to the chest AND ordering imaging is sometimes just not possible. It will slowly creep into the clinical world, but not for the next half-decade to decade. I know some here will have their heads completely in the sand and scoff at what I've said, but for those who are more level-headed, I hope the personal opinion of a clinician has helped you understand this stock and it's potential a bit better.

Expand

Cheers for your input doc.....I think 5-10 years for gold standard of care acceptance is way off, time will tell.
The medical world has been in the same diagnosis rut for a hell of a long time. I agree with you that a percentage of the GP's will be slow.....
But TOOL that's a much higher accurate outcome without the need for X-ray, blood test etc with a $10 price tag, (please don't tell me a X-ray is cheaper )..and as you say will be a driving force in the Telehealth world, why would it not be accepted quickly in the GP/hospital world.....are you really a junior doctor???? Or a radiologist perhaps?

RAP Price at posting: 32.5¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

What's causing the cost-of-living crisis, and how to navigate it

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

There are more pages in this discussion • 1,090 more messages in this thread...

First 515 Last

Add RAP (ASX) to my watchlist